Brief: Lyell Immunopharma Reports Dose-Dependent Clinical Activity From Phase 1 Trial
26/06/2024 12:08
June 26 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* LYELL IMMUNOPHARMA REPORTS DOSE-DEPENDENT CLINICAL
ACTIVITY FROM
PHASE 1 TRIAL OF LYL797, A ROR1-TARGETED CAR-T CELL PRODUCT
CANDIDATE ENHANCED WITH ITS PROPRIETARY ANTI-EXHAUSTION
TECHNOLOGY
* LYELL IMMUNOPHARMA INC - LYL797 SHOWS 40% OBJECTIVE
RESPONSE
RATE IN TNBC
* LYELL IMMUNOPHARMA INC: IND SUBMISSION COMPLETED FOR
LYL119
Source text for Eikon: ID:nGNX79H1yk
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma